Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16940
Title: Q-Vax Q fever vaccine failures, Victoria, Australia 1994-2013
Authors: Bond, Katherine A;Franklin, Lucinda J;Sutton, Brett;Firestone, Simon M
Issue Date: 10-Nov-2017
EDate: 2017-11-10
Citation: Vaccine 2017; online first: 10 November
Abstract: Q-Vax®, a whole cell formalin inactivated vaccine, is currently the only licensed Q fever vaccine for humans world-wide. Efficacy is high, although vaccine failures have been described for those vaccinated within the incubation of a naturally acquired infection. In Australia, it is widely used to prevent occupational acquisition of Q fever and is the mainstay for outbreak control. A retrospective review of all notified cases of acute Q fever to the Victorian department of health, 1993–2013, revealed 34 of 659 cases were previously vaccinated and 10 cases were positive on pre-vaccination screening, precluding vaccination. Twenty-one cases described high-risk exposures for C. burnetii prior to and within 15 days post vaccination and are likely to have been vaccinated within the incubation period of a natural infection. Thirteen cases described symptom onset more than 15 days post vaccination and thus may represent the first described series of Q-Vax vaccine failures following appropriate vaccination.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16940
DOI: 10.1016/j.vaccine.2017.10.088
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/29132996
Type: Journal Article
Subjects: Q fever
Coxiella burnetii
Q-Vax®
Vaccine failure
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.